Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | REN | P00797 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16896981 | 1.00 | CYP1A2 (0.38) | CYP1A2ALDH1A1KMT2ACTSLCTSB | |
| SCHEMBL11003542 | 0.95 | CYP1A2 (0.39) | CYP1A2ALDH1A1KMT2ACTSLCTSB | |
| SCHEMBL16896984 | 0.95 | CYP1A2 (0.39) | CYP1A2ALDH1A1KMT2ACTSLCTSB | |
| SCHEMBL11003161 | 0.93 | CYP1A2 (0.36) | CYP1A2ALDH1A1KMT2ACTSLCTSB | |
| SCHEMBL10998499 | 0.88 | CYP1A2 (0.44) | CYP1A2ALDH1A1KMT2ACTSLCTSB | |
| SCHEMBL10997682 | 0.87 | CYP1A2 (0.38) | CYP1A2ALDH1A1KMT2ACTSLCTSB | |
| SCHEMBL11001369 | 0.87 | CYP1A2 (0.38) | CYP1A2ALDH1A1KMT2ACTSLCTSB | |
| SCHEMBL10998666 | 0.85 | CYP1A2 (0.34) | CYP1A2ALDH1A1KMT2ACTSLCTSB | |
| SCHEMBL11001837 | 0.84 | CYP1A2 (0.44) | CYP1A2ALDH1A1KMT2ACTSLCTSB | |
| SCHEMBL11254010 | 0.82 | CYP1A2 (0.48) | CYP1A2ALDH1A1KMT2ACTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3094613-A1 | PROCESSES FOR THE SYNTHESIS OF CHIRAL 1-ALKANOLS | Purdue Research Foundation, Inc. (US) | 2016-11-23 | — | — | EP | claimed |
| WO-2015106045-A1 | PROCESSES FOR THE SYNTHESIS OF CHIRAL 1-ALKANOLS | PURDUE RESEARCH FOUNDATION (US) | 2015-07-16 | — | — | WO | claimed |
| US-10000432-B2 | Processes for the synthesis of chiral 1-alkanols | PURDUE RESEARCH FOUNDATION (US) | 2018-06-19 | — | — | US | disclosed |
| EP-3094613-A1 | PROCESSES FOR THE SYNTHESIS OF CHIRAL 1-ALKANOLS | Purdue Research Foundation, Inc. (US) | 2016-11-23 | — | — | EP | disclosed |
| US-20160332940-A1 | PROCESSES FOR THE SYNTHESIS OF CHIRAL 1-ALKANOLS | PURDUE RESEARCH FOUNDATION (US) | 2016-11-17 | — | — | US | disclosed |
| WO-2015106045-A1 | PROCESSES FOR THE SYNTHESIS OF CHIRAL 1-ALKANOLS | PURDUE RESEARCH FOUNDATION (US) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332940-A1 | PROCESSES FOR THE SYNTHESIS OF CHIRAL 1-ALKANOLS | CYP51A1, ALKBH3, ALKBH1 | CYP1A2 20/4885ALDH1A1 500/4885KMT2A 923/4885 |
| US-10000432-B2 | Processes for the synthesis of chiral 1-alkanols | CYP51A1, ALKBH3, ALKBH1 | CYP1A2 20/4885ALDH1A1 500/4885KMT2A 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.